Dyne Therapeutics Inc.
Organization details
- Legal name
- Dyne Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- DYN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001818794
- EIN
- 36-4883909
Board of directors
-
Barry E. Greene · DirectorSince 2026
-
Brian S. Posner · DirectorSince 2025
-
Carlo Incerti · DirectorSince 2023
-
Catherine Stehman-Breen · DirectorSince 2023
-
David Charles Lubner · DirectorSince 2023
-
Dirk Kersten · DirectorSince 2023
-
Edward Hurwitz · DirectorSince 2023
-
Jason P. Rhodes · DirectorSince 2023
-
John Cox · Director · CEO & PresidentSince 2024
-
Joshua T. Brumm · Director · CEO & PresidentSince 2023
-
Vikram Karnani · DirectorSince 2025
Chief executives
Director election results
Annual meeting of June 5, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
87.4%
-
91.5%
-
99.6%
Board connections
7 of this board's directors also sit on 10 other boards. 9 are in the same sector.
-
Crescent Biopharma Inc. Same sectorvia David Charles Lubner and Joshua T. Brumm
- via Brian S. Posner
-
Biogen Inc. Same sectorvia Brian S. Posner
-
Braveheart Bio Inc. Same sectorvia David Charles Lubner
-
City Therapeutics Inc. Same sectorvia Barry E. Greene
-
Collegium Pharmaceutical Inc. Same sectorvia Vikram Karnani
-
Karyopharm Therapeutics Inc. Same sectorvia Barry E. Greene
-
MacroGenics Inc. Same sectorvia Edward Hurwitz
-
Tenaya Therapeutics Inc. Same sectorvia Catherine Stehman-Breen
-
Vor Biopharma Inc. Same sectorvia David Charles Lubner
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $314,840
- 8 purchases by 1 insider
- Sold, last 12 months
- $168,617,827
- 122 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 20, 2026 | Kerr Douglas Officer (Head of R&D and CMO) | Grant or award | +8,000 | — | — |
| Oct 2, 2026 | Brian S. Posner Director | Open-market purchase | +2,500 | $16.00 | $40,000 |
| Sep 8, 2026 | John Cox Director, Officer (CEO & President) | Open-market sale | −5,658 | $18.88 | $106,823 |
| Sep 8, 2026 | Kerr Douglas Officer (Chief Medical Officer) | Open-market sale | −1,290 | $18.88 | $24,355 |
| Sep 8, 2026 | Friedl-Naderer Johanna Officer (Chief Commercial Officer) | Open-market sale | −185 | $18.88 | $3,493 |
| Sep 4, 2026 | Kerr Douglas Officer (Chief Medical Officer) | Open-market sale | −3,745 | $24.35 | $91,191 |
| Sep 4, 2026 | Friedl-Naderer Johanna Officer (Chief Commercial Officer) | Open-market sale | −900 | $24.35 | $21,915 |
| Aug 14, 2026 | Jason P. Rhodes Director | Open-market sale | −1,359,674 | $25.00 | $33,991,850 |
| Aug 14, 2026 | Jason P. Rhodes Director | Open-market sale | −478,377 | $25.00 | $11,959,425 |
| Aug 14, 2026 | Jason P. Rhodes Director | Open-market sale | −322,465 | $25.00 | $8,061,625 |
| Aug 13, 2026 | John Cox Director, Officer (CEO & President) | Open-market sale | −4,986 | $26.28 | $131,032 |
| Aug 13, 2026 | Jason P. Rhodes Director | Open-market sale | −268,354 | $26.20 | $7,030,875 |
| Aug 13, 2026 | Erick Lucera Officer (Chief Financial Officer) | Open-market sale | −1,797 | $26.28 | $47,225 |
| Aug 13, 2026 | Kerr Douglas Officer (Chief Medical Officer) | Open-market sale | −1,556 | $26.28 | $40,892 |
| Aug 13, 2026 | Friedl-Naderer Johanna Officer (Chief Commercial Officer) | Open-market sale | −226 | $26.28 | $5,939 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Dyne Therapeutics Inc.
Who is the CEO of Dyne Therapeutics Inc.?
John Cox has been Dyne Therapeutics Inc.'s CEO & President since March 2024.
How many directors are on Dyne Therapeutics Inc.'s board?
Dyne Therapeutics Inc.'s board has 11 directors: Barry E. Greene, Brian S. Posner, Carlo Incerti, Catherine Stehman-Breen, David Charles Lubner, Dirk Kersten, Edward Hurwitz, Jason P. Rhodes, John Cox, Joshua T. Brumm and 1 other.
Are Dyne Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Dyne Therapeutics Inc. insiders bought $314,840 of shares in 8 purchases and sold $168.6 million of shares in 122 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="dyne-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.